Allergy Therapeutics
AGY · AIM · Health Care · mcap £306m · 4.8p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 29 Jul 26 | Trading update | Trading update for the year ended 30 June 2026
("Allergy Therapeutics" or the "Company" or the "Group") |
+9.7% |
| 28 Jul 26 | Board change | Appointment of Executive Chairman
28 July 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces the appointment of Helge Weiner-Trapness as Executive Cha |
−0.4% |
| 30 Jun 26 | Routine | Vesting of Options under Long-Term Incentive Plan | |
| 15 Jun 26 | Long Term Incentive Awards
15 June 2026 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that on 13 June 2026 it made a new long term incentive award (the |
+0.0% | |
| 12 Jun 26 | Allergy Therapeutics to present at EAACI 2026
Allergy Therapeutics to present pollen and food allergy research data |
−1.2% | |
| 31 Mar 26 | Results | Half-year Results
("Allergy Therapeutics" or the "Company" or the "Group") |
−1.9% |
| 12 Mar 26 | Director dealing | PDMR Dealings & Shareholding Update | |
| 04 Mar 26 | Results | Positive Biomarker Results from PROTECT Trial
Positive biomarker results from the PROTECT Phase I/IIa trial following achievement of the primary safety endpoint |
−6.0% |
| 26 Feb 26 | Allergy Therapeutics presents progress at AAAAI
Allergy Therapeutics presents further scientific progress in its pollen and food-allergy research portfolio at the 2026 AAAAI Annual Meeting |
+0.0% | |
| 23 Feb 26 | Update on funding and total voting rights
23 February 2026 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today provides an update on the Group's funding and working capital pos |
+9.6% | |
| 30 Jan 26 | Chief Strategy Officer and Board appointments
Allergy Therapeutics announces the appointments of Helge Weiner-Trapness as Chief Strategy Officer and Executive Director, and Lawrence Allen Wang as Independent Non-Executive Director |
+0.0% | |
| 29 Jan 26 | Routine | Result of AGM | |
| 28 Jan 26 | Routine | Grant of Options under Long Term Incentive Scheme | |
| 19 Jan 26 | Trading update | Half Year Trading Update
("Allergy Therapeutics" or the "Company" or the "Group") |
−4.1% |
| 06 Jan 26 | Notice of AGM
06 January 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, has today published its Notice of Annual General Meeting following pub |
+4.4% | |
| 29 Dec 25 | Result of General Meeting
Results of General Meeting and Posting of Annual Report 2025 |
+0.4% | |
| 16 Dec 25 | Grassmuno® marketing authorisation in Germany
("Allergy Therapeutics" or the "Company" or the "Group") |
+3.7% | |
| 12 Dec 25 | Authority for allotment of New Shares
Authority for allotment of up to 610,000,000 New Shares and disapplication of pre-emption rights to facilitate a Potential Equity Raise |
−4.7% | |
| 11 Dec 25 | Results | Prelim Results and publication of Annual Report
("Allergy Therapeutics" or the "Group" or the "Company") |
−0.5% |
| 09 Dec 25 | Primary Safety Endpoint Met in PROTECT trial
PROTECT Phase I/IIa trial meets primary safety endpoint at highest planned dose |
+0.0% | |
| 06 Nov 25 | Company to Evaluate Dual Listing on HKEX
Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") |
+2.4% | |
| 30 Oct 25 | G308 Phase III Year 2 Patient Screening Starts
Grass MATA MPL in paediatric patients - commencement of patient screening |
−6.5% | |
| 29 Oct 25 | Warrant Exercise and Paydown of Debt
Repayment of the Entire Balance under the Shareholder Facility |
+3.0% | |
| 16 Oct 25 | Further progress in Phase I/IIa PROTECT trial
Allergy Therapeutics announces further positive progress in Phase I/IIa PROTECT trial evaluating safety and tolerability of short-course peanut allergy vaccine candidate |
+3.8% |
Company filings. Not investment advice.